KHC
CRL icon

Koesten Hirschmann & Crabtree’s Charles River Laboratories CRL Stock Holding History

Koesten Hirschmann & Crabtree’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-8
Closed -$1.58K – 202
2024
Q3 		$1.58K Hold
8
– – ﹤0.01% 166
2024
Q2 		$2.17K Hold
8
– – ﹤0.01% 173
2024
Q1 		$2.17K Buy
+8
New +$1.91K ﹤0.01% 173

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Impactive Capital New York City, New York $1.4B AUM 13.97% 1-Year Est. Return
MG
Meritage Group San Francisco, California $2.6B AUM 15.71% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Koesten Hirschmann & Crabtree's CRL Position: Q4 2024 in Review

Koesten Hirschmann & Crabtree sold out of Charles River Laboratories (CRL) in Q4 2024, closing a stake of 8 shares — an estimated $1.58K sold.

Koesten Hirschmann & Crabtree first reported a position in CRL in Q1 2024 and held it in 3 quarters. The position peaked at $2.17K in Q2 2024. 637 funds tracked by Wall St. Rank hold CRL as of Q4 2024.

  • Koesten Hirschmann & Crabtree reported no remaining Charles River Laboratories position as of Q4 2024 after selling out during the quarter.
  • Koesten Hirschmann & Crabtree sold 8 Charles River Laboratories shares in Q4 2024, an estimated $1.58K.
  • Koesten Hirschmann & Crabtree first reported a position in Charles River Laboratories in Q1 2024 and held it in 3 quarters.
  • Koesten Hirschmann & Crabtree's Charles River Laboratories position peaked at $2.17K in Q2 2024.
  • 637 funds tracked by Wall St. Rank held Charles River Laboratories as of Q4 2024.

Based on Koesten Hirschmann & Crabtree's 13F filing for Q4 2024, filed 14 Feb 2025.